| XLS |
|
|
Equity capital |
Reserves |
Gains/losses recognized |
|
|
| |||||
|
€ million |
General |
Subscribed |
Capital |
Retained |
Actuarial |
Available-for-sale |
Derivative |
Exchange |
Equity attributable to shareholders |
Non-controlling |
Equity |
|
Balance as of January 1, 2010 |
397.2 |
168.0 |
3,813.7 |
4,733.7 |
–228.7 |
18.8 |
47.5 |
509.9 |
9,460.1 |
53.5 |
9,513.6 |
|
Profit after tax |
– |
– |
– |
585.6 |
– |
– |
– |
– |
585.6 |
10.4 |
596.0 |
|
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
–75.3 |
–1.7 |
–46.4 |
773.0 |
649.6 |
5.0 |
654.6 |
|
Comprehensive income |
– |
– |
– |
585.6 |
–75.3 |
–1.7 |
–46.4 |
773.0 |
1,235.2 |
15.4 |
1,250.6 |
|
Dividend payments |
– |
– |
– |
–64.6 |
– |
– |
– |
– |
–64.6 |
–8.4 |
–73.1 |
|
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–163.9 |
– |
– |
– |
– |
–163.9 |
– |
–163.9 |
|
Changes in scope of consolidation/Other |
– |
– |
– |
6.5 |
– |
– |
– |
– |
6.5 |
–1.7 |
4.8 |
|
Balance as of Sep. 30, 2010 |
397.2 |
168.0 |
3,813.7 |
5,097.3 |
–304.0 |
17.1 |
1.1 |
1,282.9 |
10,473.3 |
58.8 |
10,532.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2011 |
397.2 |
168.0 |
3,813.7 |
5,040.9 |
–370.4 |
–3.1 |
–61.1 |
1,344.6 |
10,329.8 |
42.0 |
10,371.8 |
|
Profit after tax |
– |
– |
– |
481.8 |
– |
– |
– |
– |
481.8 |
8.2 |
490.0 |
|
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
–4.3 |
0.5 |
–31.8 |
–68.9 |
–104.5 |
–2.7 |
–107.2 |
|
Comprehensive income |
– |
|
– |
481.8 |
–4.3 |
0.5 |
–31.8 |
–68.9 |
377.3 |
5.5 |
382.8 |
|
Dividend payments |
– |
– |
– |
–80.8 |
– |
– |
– |
– |
–80.8 |
–3.8 |
–84.6 |
|
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–233.0 |
– |
– |
– |
– |
–233.0 |
– |
–233.0 |
|
Changes in scope of consolidation/Other |
– |
– |
– |
–1.8 |
– |
– |
– |
– |
–1.8 |
1.4 |
–0.4 |
|
Balance as of Sep. 30, 2011 |
397.2 |
168.0 |
3,813.7 |
5,207.1 |
–374.7 |
–2.6 |
–92.9 |
1,275.7 |
10,391.5 |
45.1 |
10,436.6 |
